Proximagen proposes £30m IPO
Drug developer Proximagen, a spin out from King’s College, will join AIM at the end of the month with a £30 million starting price tag.
News
Drug developer Proximagen, a spin out from King’s College, will join AIM at the end of the month with a £30 million starting price tag.
News
Partner content
Accounting and Finance Software
Accounting and Finance Software